Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

Prior treatment

• Presence of cognitive dysfunction prior to stroke assessed by informants, that is, the average score of Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE, 16-item version) during the screening period was ≥ 3.19 and the total score was ≥ 51.
• Patients who have been diagnosed with severe mental disorders prior to stroke.
• Thrombectomy or interventional therapy has been applied or planned after this episode.
• history of major surgery within 4 weeks prior to enrollment;
• participation in another clinical study within 30 days prior to randomization, or ongoing participation in another clinical study;

Other illness

• Presence of intracranial hemorrhagic disease confirmed by brain imaging.
• History of malignancy; except for subjects with non-melanoma skin cancer (NMSC) that has been successfully treated and limited cervical cancer in situ. Subjects with a diagnosis of malignancy after enrollment may continue to participate in the study or not at the discretion of the investigator and at the discretion of the subject;
• Suffering from a severe systemic disease with an expected survival period of \<1 year;

Lab values

• Poorly controlled diabetes (fasting blood glucose \>10mmol/L and/or HbA1c\>8%).
• Patients have received the cognitive enhancers and other anti-dementia drugs within 1 month before the screening period, including but not limited to cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists (memantine) and other drugs (such as mannitol sodium capsules, Ginkgo Biloba Extract Injection, Compound Ginkgo Biloba Tablets, oxiracetam, aniracetam, piracetam，nicergoline, Lecanemab, Donanemab, Aducanumab, etc. ).
• Have been diagnosed with severe active liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc.; or ALT or AST \> 2.0 × ULN.
• Has been diagnosed with severe active kidney disease, renal insufficiency; or serum creatinine \> 1.5 × ULN.
• hypersensitivity to dextran camphene, natural ice chips or edaravone or excipients (mannitol, copovidone, microcrystalline cellulose, cross-linked povidone, silicon dioxide, magnesium stearate);

Other

• Severe disturbance of consciousness: NIHSS 1a level of consciousness item score \> 1 point.
• Transient ischemic attack (TIA).
• Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 120 mmHg after blood pressure control.
• Patients with contraindications to MRI imaging.
• For subjects who are scheduled to undergo EEG examination, Patients with contraindications for EEG examination.
• Severe limb hemiplegia and aphasia and significantly affect cognitive function assessment.
• pregnancy, lactation, and patients planning pregnancy;
• in the opinion of the investigator, not suitable for participation in this clinical study.

• Age ≥ 40 years and ≤ 80 years, male or female.
• Diagnosed as ischemic stroke, no significant pre-stroke functional disability (mRS score ≤ 1prior to stroke onset).
• The National Institutes of Stroke Scale score ≤ 20 points.
• Time from onset to obtained informed consent form is within 7 days (including 7 days).
• Presence of cognitive dysfunction at screening, i.e., MoCA scale score \< 22.
• Patients with good cognitive function prior to stroke, without significant cognitive dysfunction and dementia.
• Education level: primary school or above, and can complete the cognitive function test required per investigator's judgement.
• female subjects of childbearing potential and male subjects whose female partners are of childbearing potential must be willing to and use contraception during the study treatment and within 30 days after the last dose of study drug and have no plans to donate sperm or eggs; female subjects of childbearing potential will have a negative pregnancy test;
• obtain voluntary signed informed consent from the patient or his/her legal representative approved by the Ethics Committee.